Drug Profile
AK 114
Alternative Names: AK114Latest Information Update: 25 Jan 2022
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Anti-inflammatories; Antibodies; Eye disorder therapies
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammation
- Discontinued Autoimmune disorders; Eye disorders
Most Recent Events
- 20 Jan 2022 Akeso plans a phase I trial for Solid tumours (Metastatic disease, Late-stage disease) in Australia (SC, Injection) (NCT05200273)
- 11 Aug 2020 Discontinued - Preclinical for Autoimmune disorders in China (Parenteral) before August 2020 (Akeso Biopharma pipeline August 2020)
- 11 Aug 2020 Discontinued - Preclinical for Eye disorders in China (Parenteral) before August 2020 (Akeso Biopharma pipeline August 2020)